20 results on '"Chen, Bernadette"'
Search Results
2. Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia
- Author
-
Jin, Yi, Calvert, Thomas J., Chen, Bernadette, Chicoine, Louis G., Joshi, Mandar, Bauer, John Anthony, Liu, Yusen, and Nelin, Leif D.
- Subjects
Nitric oxide -- Health aspects ,Pulmonary hypertension -- Development and progression ,Pulmonary hypertension -- Genetic aspects ,Arginase -- Health aspects ,Pulmonary circulation -- Models ,Hypoxia -- Development and progression ,Hypoxia -- Genetic aspects ,Lungs -- Blood-vessels ,Lungs -- Models ,Biological sciences - Abstract
The mitogen-activated protein (MAP) kinases are involved in cellular responses to many stimuli, including hypoxia. MAP kinase signaling is regulated by a family of phosphatases that include MAP kinase phosphatase-I (MKP-1). We hypothesized that mice lacking the Mkp-1 gene would have exaggerated chronic hypoxia-induced pulmonary hypertension. Wild-type (WT) and [Mkp-1.sup.-/-] mice were exposed to either 4 wk of normoxia or hypobaric hypoxia. Following chronic hypoxia, both genotypes demonstrated elevated right ventricular pressures, right ventricular hypertrophy as demonstrated by the ratio of the right ventricle to the left ventricle plus septum weights [RV(LV + S)], and greater vascular remodeling. However, the right ventricular systolic pressures, the RV/(LV + S), and the medial wall thickness of 100- to 300-[micro]m vessels was significantly greater in the [Mkp-1.sup.-/-] mice than in the WT mice following 4 wk of hypobaric hypoxia. Chronic hypoxic exposure caused no detectable change in eNOS protein levels in the lungs in either genotype: however, [Mkp-1.sup.-/-] mice had lower levels of eNOS protein and lower lung NO production than did WT mice. No iNOS protein was detected in the lungs by Western blotting in any condition in either genotype. Both arginase I and arginase II protein levels were greater in the lungs of hypoxic [Mkp-1.sup.-/-] mice than those in hypoxic WT mice. Lung levels of proliferating cell nuclear antigen were greater in hypoxic [Mkp-1.sup.-/-] than in hypoxic WT mice. These data are consistent with the concept that MKP-1 acts to restrain hypoxia-induced arginase expression and thereby reduces vascular remodeling and the severity of pulmonary hypertension. nitric oxide synthase; arginase; pulmonary vascular remodeling doi: 10.1152/ajpheart.00813.2009.
- Published
- 2010
3. Hypoxia-induced proliferation of human pulmonary microvascular endothelial cells depends on epidermal growth factor receptor tyrosine kinase activation
- Author
-
Toby, Inimary T., Chicoine, Louis G., Cui, Hongmei, Chen, Bernadette, and Nelin, Leif D.
- Subjects
Cell proliferation -- Analysis ,Hypoxia -- Physiological aspects ,Arginase -- Physiological aspects ,Arginase -- Health aspects ,Vascular endothelium -- Properties ,Vascular endothelium -- Health aspects ,Epidermal growth factor -- Physiological aspects ,Respiratory physiology -- Research ,Biological sciences - Abstract
We hypothesized that hypoxia would activate epidermal growth factor receptor (EGFR) tyrosine kinase, leading to increased arginase expression and resulting in proliferation of human pulmonary microvascular endothelial cell (hPMVEC). To test this hypothesis, hPMVEC were incubated in normoxia (20% 02, 5% C[O.sub.2]) or hypoxia (1% [O.sub.2], 5% C[O.sub.2]). Immunoblotting for EGFR and proliferating cell nuclear antigen was done, and protein levels of both total EGFR and proliferating cell nuclear antigen were greater in hypoxic hPMVEC than in normoxic hPMVEC. Furthermore, hypoxic hPMVEC had greater levels of EGFR activity than did normoxic hPMVEC. Hypoxic hPMVEC had a twofold greater level of proliferation compared with normoxic controls, and this increase in proliferation was prevented by the addition of AG-1478 (a pharmacological inhibitor of EGFR). Immunoblotting for arginase I and arginase II demonstrated a threefold induction in arginase II protein levels in hypoxia, with little change in arginase I protein levels. The hypoxic induction of arginase II protein was prevented by treatment with AG-1478. Proliferation assays were performed in the presence of arginase inhibitors, and hypoxia-induced proliferation was also prevented by arginase inhibition. Finally, treatment with an EGFR small interfering RNA prevented hypoxia-induced profiferation and urea production. These findings demonstrate that hypoxia activates EGFR tyrosine kinase, leading to arginase expression and thereby promoting proliferation in hPMVEC. vascular remodeling; L-arginine; pulmonary hypertension doi: 10.1152/ajplung.00122.2009.
- Published
- 2010
4. Hypoxia promotes human pulmonary artery smooth muscle cell proliferation through induction of arginase
- Author
-
Chen, Bernadette, Calvert, Andrea E., Cui, Hongmei, and Nelin, Leif D.
- Subjects
Hypertension -- Care and treatment ,Hypertension -- Research ,Arginase -- Physiological aspects ,Arginase -- Genetic aspects ,Arginase -- Research ,Cell proliferation -- Physiological aspects ,Cell proliferation -- Research ,Smooth muscle -- Physiological aspects ,Smooth muscle -- Research ,Biological sciences - Abstract
Chen B, Calvert AE, Cui H, Nelin LD. Hypoxia promotes human pulmonary artery smooth muscle cell proliferation through induction of arginase. Am J Physiol Lung Cell Mol Physiol 297 : L1151-L1159, 2009. First published October 2, 2009; doi: 10.1152/ajplung.00183.2009.--Vascular remodeling and smooth muscle cell proliferation are hallmark pathogenic features of pulmonary artery hypertension (PAH). Alterations in the metabolism of L-arginine via arginase and nitric oxide synthase play a critical role in the endothelial dysfunction seen in PAH. L-arginine metabolism by arginase produces L-ornithine and urea. L-ornithine is a precursor for polyamine and proline synthesis, ultimately leading to an increase in cellular proliferation. Given the integral role of the smooth muscle layer in the pathogenesis of hypoxia-induced PAH, we hypothesized that hypoxia would increase cellular proliferation via arginase induction in human pulmonary artery smooth muscle cells (hPASMC). We found that arginase II mRNA and protein expression were significantly increased in cultured hPASMC exposed to 1% [O.sub.2] for 24 and 48 h, which coincided with an increase in arginase activity at 48 h. There were no hypoxia-induced changes in levels of arginase I mRNA or protein in cultured hPASMC. Exposure to hypoxia resulted in more than one and a half times as many viable ceils after 120 h than normoxic exposure. The addition of the arginase inhibitor, S-(2-boronoethyl)-L-cysteine, completely prevented both the hypoxia-induced increase in arginase activity and proliferation in hPASMC. Furthermore, transfection of small interfering RNA (siRNA) targeting arginase II in hPASMC resulted in knockdown of arginase II protein levels and complete prevention of the hypoxia-induced cellular proliferation. These data support our hypothesis that hypoxia increases proliferation of hPASMC through the induction of arginase II. pulmonary hypertension; L-arginine; vascular remodeling doi: 10.1152/ajplung.00183.2009.
- Published
- 2009
5. Hypoxic proliferation requires EGFR-mediated ERK activation in human pulmonary microvascular endothelial cells
- Author
-
White, Hilary A., primary, Jin, Yi, additional, Chicoine, Louis G., additional, Chen, Bernadette, additional, Liu, Yusen, additional, and Nelin, Leif D., additional
- Published
- 2017
- Full Text
- View/download PDF
6. Hypoxia induces arginase II expression and increases viable human pulmonary artery smooth muscle cell numbers via AMPKα1 signaling
- Author
-
Xue, Jianjing, primary, Nelin, Leif D., additional, and Chen, Bernadette, additional
- Published
- 2017
- Full Text
- View/download PDF
7. The Src family tyrosine kinases src and yes have differential effects on inflammation-induced apoptosis in human pulmonary microvascular endothelial cells
- Author
-
Nelin, Leif D., primary, White, Hilary A., additional, Jin, Yi, additional, Trittmann, Jennifer K., additional, Chen, Bernadette, additional, and Liu, Yusen, additional
- Published
- 2016
- Full Text
- View/download PDF
8. Resveratrol prevents hypoxia-induced arginase II expression and proliferation of human pulmonary artery smooth muscle cells via Akt-dependent signaling
- Author
-
Chen, Bernadette, primary, Xue, Jianjing, additional, Meng, Xiaomei, additional, Slutzky, Jessica L., additional, Calvert, Andrea E., additional, and Chicoine, Louis G., additional
- Published
- 2014
- Full Text
- View/download PDF
9. Arginase II is a target of miR-17-5p and regulates miR-17-5p expression in human pulmonary artery smooth muscle cells
- Author
-
Jin, Youpeng, primary, Jin, Yi, additional, Chen, Bernadette, additional, Tipple, Trent E., additional, and Nelin, Leif D., additional
- Published
- 2014
- Full Text
- View/download PDF
10. Thioredoxin-1 mediates hypoxia-induced pulmonary artery smooth muscle cell proliferation
- Author
-
Chen, Bernadette, primary, Nelin, Viktoria E., additional, Locy, Morgan L., additional, Jin, Yi, additional, and Tipple, Trent E., additional
- Published
- 2013
- Full Text
- View/download PDF
11. Chronic hypoxia decreases arterial and venous compliance in isolated perfused rat lungs: an effect that is reversed by exogenous l-arginine
- Author
-
Jin, Yi, primary, Chen, Bernadette, additional, Calvert, Thomas J., additional, Chicoine, Louis G., additional, Liu, Yusen, additional, and Nelin, Leif D., additional
- Published
- 2013
- Full Text
- View/download PDF
12. Mice deficient in Mkp -1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia.
- Author
-
Yi Jin, Calvert, Thomas J., Chen, Bernadette, Chicoine, Louis G., Joshi, Mandar, Bauer, John Anthony, Yusen Liu, and Nelin, Leif D.
- Subjects
MITOGEN-activated protein kinases ,HYPOXEMIA ,PULMONARY blood vessels ,CARDIAC hypertrophy ,PULMONARY hypertension treatment ,LABORATORY mice ,DISEASE risk factors - Abstract
The mitogen-activated protein (MAP) kinases are involved in cellular responses to many stimuli, including hypoxia. MAP kinase signaling is regulated by a family of phosphatases that include MAP kinase phosphatase-1 (MKP-1). We hypothesized that mice lacking the Mkp-1 gene would have exaggerated chronic hypoxia-induced pulmonary hypertension. Wild-type (WT) and
Mkp-1 mice were exposed to either 4 wk of normoxia or hypobaric hypoxia. Following chronic hypoxia, both genotypes demonstrated elevated right ventricular pressures, right ventricular hypertrophy as demonstrated by the ratio of the right ventricle to the left ventricle plus septum weights [RV(LV + S)], and greater vascular remodeling. However, the right ventricular systolic pressures, the RV/(LV + S), and the medial wall thickness of 100- to 300-μm vessels was significantly greater in the Mkp-1-/- -/- mice than in the WT mice following 4 wk of hypobaric hypoxia. Chronic hypoxic exposure caused no detectable change in eNOS protein levels in the lungs in either genotype; however, Mkp-1-/- mice had lower levels of eNOS protein and lower lung NO production than did WT mice. No iNOS protein was detected in the lungs by Western blotting in any condition in either genotype. Both arginase I and arginase 11 protein levels were greater in the lungs of hypoxic Mkp-1-/- mice than those in hypoxic WT mice. Lung levels of proliferating cell nuclear antigen were greater in hypoxic Mkp-1-/- than in hypoxic WT mice. These data are consistent with the concept that MKP-1 acts to restrain hypoxia-induced arginase expression and thereby reduces vascular remodeling and the severity of pulmonary hypertension. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
13. Cyclooxygenase-2 deficiency attenuates lipopolysaccharide-induced inflammation, apoptosis, and acute lung injury in adult mice.
- Author
-
Nelin LD, Jin Y, Chen B, Liu Y, Rogers LK, and Reese J
- Subjects
- Acute Lung Injury chemically induced, Acute Lung Injury enzymology, Acute Lung Injury pathology, Animals, Caspase 3 metabolism, Caspase 9 metabolism, Chemokine CCL2 genetics, Chemokine CCL2 metabolism, Cyclooxygenase 2 genetics, Disease Models, Animal, Female, Interleukin-10 genetics, Interleukin-10 metabolism, Lipopolysaccharides, Lung pathology, Male, Mice, Knockout, Pneumonia chemically induced, Pneumonia enzymology, Pneumonia pathology, Signal Transduction, Tumor Necrosis Factor-alpha genetics, Tumor Necrosis Factor-alpha metabolism, Mice, Acute Lung Injury prevention & control, Apoptosis, Cyclooxygenase 2 deficiency, Lung enzymology, Pneumonia prevention & control
- Abstract
Many lung diseases are caused by an excessive inflammatory response, and inflammatory lung diseases are often modeled using lipopolysaccharide (LPS) in mice. Cyclooxygenase-2 (COX-2) encoded by the Ptgs2 gene is induced in response to inflammatory stimuli including LPS. The objective of this study was to test the hypothesis that mice deficient in COX-2 ( Ptgs2
-/- ) will be protected from LPS-induced lung injury. Wild-type (WT; CD1 mice) and Ptgs2-/- mice (on a CD1 background) were treated with LPS or vehicle for 24 h. LPS treatment resulted in histological evidence of lung injury, which was attenuated in the Ptgs2-/- mice. LPS treatment increased the mRNA levels for tumor necrosis factor-α, interleukin-10, and monocyte chemoattractant protein-1 in the lungs of WT mice, and the LPS-induced increases in these levels were attenuated in the Ptgs2-/- mice. The protein levels of active caspase-3 and caspase-9 were lower in the LPS-treated lungs of Ptgs2-/- mice than in LPS-treated WT mice, as were the number of terminal deoxynucleotide transferase dUTP nick end labeling-positive cells in lung sections. LPS exposure resulted in a greater lung wet-to-dry weight ratio (W/D) in WT mice, suggestive of pulmonary edema, while in LPS-treated Ptgs2-/- mice, the W/D was not different from controls and less than in LPS-treated WT mice. These results demonstrate that COX-2 is involved in the inflammatory response to LPS and suggest that COX-2 not only acts as a downstream participant in the inflammatory response, but also acts as a regulator of the inflammatory response likely through a feed-forward mechanism following LPS stimulation.- Published
- 2022
- Full Text
- View/download PDF
14. Hypoxic proliferation requires EGFR-mediated ERK activation in human pulmonary microvascular endothelial cells.
- Author
-
White HA, Jin Y, Chicoine LG, Chen B, Liu Y, and Nelin LD
- Subjects
- Arginase metabolism, Butadienes pharmacology, Cell Count, Cell Hypoxia drug effects, Cell Proliferation drug effects, Cell Survival drug effects, Culture Media, Conditioned pharmacology, Endothelial Cells drug effects, Enzyme Activation drug effects, Gene Knockdown Techniques, Gene Silencing drug effects, Humans, Nitriles pharmacology, Phosphorylation drug effects, Quinazolines pharmacology, RNA, Small Interfering metabolism, Tyrphostins pharmacology, p38 Mitogen-Activated Protein Kinases metabolism, Endothelial Cells enzymology, ErbB Receptors metabolism, Extracellular Signal-Regulated MAP Kinases metabolism, Lung blood supply, Microvessels pathology
- Abstract
We have previously shown that hypoxic proliferation of human pulmonary microvascular endothelial cells (hPMVECs) depends on epidermal growth factor receptor (EGFR) activation. To determine downstream signaling leading to proliferation, we tested the hypothesis that hypoxia-induced proliferation in hPMVECs would require EGFR-mediated activation of extracellular signal-regulated kinase (ERK) leading to arginase II induction. To test this hypothesis, hPMVECs were incubated in either normoxia (21% O
2 , 5% CO2 ) or hypoxia (1% O2 , 5% CO2 ) and Western blotting was performed for EGFR, arginase II, phosphorylated-ERK (pERK), and total ERK (ERK). Hypoxia led to greater EGFR, pERK, and arginase II protein levels than did normoxia in hPMVECs. To examine the role of EGFR in these hypoxia-induced changes, hPMVECs were transfected with siRNA against EGFR or a scrambled siRNA and placed in hypoxia. Inhibition of EGFR using siRNA attenuated hypoxia-induced pERK and arginase II expression as well as the hypoxia-induced increase in viable cell numbers. hPMVECs were then treated with vehicle, an EGFR inhibitor (AG1478), or an ERK pathway inhibitor (U0126) and placed in hypoxia. Pharmacologic inhibition of EGFR significantly attenuated the hypoxia-induced increase in pERK level. Both AG1478 and U0126 also significantly attenuated the hypoxia-induced increase in viable hPMVECs numbers. hPMVECs were transfected with an adenoviral vector containing arginase II (AdArg2) and overexpression of arginase II rescued the U0126-mediated decrease in viable cell numbers in hypoxic hPMVECs. Our findings suggest that hypoxic activation of EGFR results in phosphorylation of ERK, which is required for hypoxic induction of arginase II and cellular proliferation., (Copyright © 2017 the American Physiological Society.)- Published
- 2017
- Full Text
- View/download PDF
15. Hypoxia induces arginase II expression and increases viable human pulmonary artery smooth muscle cell numbers via AMPKα 1 signaling.
- Author
-
Xue J, Nelin LD, and Chen B
- Subjects
- Cell Count, Cell Survival, Enzyme Activation, Gene Knockdown Techniques, Humans, RNA, Small Interfering metabolism, Adenylate Kinase metabolism, Arginase metabolism, Hypoxia enzymology, Hypoxia pathology, Myocytes, Smooth Muscle enzymology, Myocytes, Smooth Muscle pathology, Pulmonary Artery pathology, Signal Transduction
- Abstract
Pulmonary artery smooth muscle cell (PASMC) proliferation is one of the hallmark features of hypoxia-induced pulmonary hypertension. With only supportive treatment options available for this life-threatening disease, treating and preventing the proliferation of PASMCs is a viable therapeutic option. A key promoter of hypoxia-induced increases in the number of viable human PASMCs is arginase II, with attenuation of viable cell numbers following pharmacologic inhibition or siRNA knockdown of the enzyme. Additionally, increased levels of arginase have been demonstrated in the pulmonary vasculature of patients with pulmonary hypertension. The signaling pathways responsible for the hypoxic induction of arginase II in PASMCs, however, remain unknown. Hypoxia is a recognized activator of AMPK, which is known to be expressed in human PASMCs (hPASMCs). Activation of AMPK by hypoxia has been shown to promote cell survival in PASMCs. In addition, pharmacologic agents targeting AMPK have been shown to attenuate chronic hypoxia-induced pulmonary hypertension in animal models. The present studies tested the hypothesis that hypoxia-induced arginase II expression in hPASMCs is mediated through AMPK signaling. We found that pharmacologic inhibitors of AMPK, as well as siRNA knockdown of AMPKα1, prevented hypoxia-induced arginase II. The hypoxia-induced increase in viable hPASMC numbers was also prevented following both pharmacologic inhibition and siRNA knockdown of AMPK. Furthermore, we demonstrate that overexpression of AMPK induced arginase II protein expression and viable cells numbers in hPASMCs., (Copyright © 2017 the American Physiological Society.)
- Published
- 2017
- Full Text
- View/download PDF
16. The Src family tyrosine kinases src and yes have differential effects on inflammation-induced apoptosis in human pulmonary microvascular endothelial cells.
- Author
-
Nelin LD, White HA, Jin Y, Trittmann JK, Chen B, and Liu Y
- Subjects
- Caspase 3 metabolism, Cell Survival, Cells, Cultured, Endothelium, Vascular immunology, Endothelium, Vascular pathology, Humans, Lipopolysaccharides pharmacology, MAP Kinase Signaling System, Microvessels enzymology, Microvessels immunology, Respiratory Distress Syndrome enzymology, Respiratory Distress Syndrome immunology, Respiratory Distress Syndrome pathology, Apoptosis, Endothelial Cells physiology, Proto-Oncogene Proteins c-yes physiology, src-Family Kinases physiology
- Abstract
Endothelial cells are essential for normal lung function: they sense and respond to circulating factors and hemodynamic alterations. In inflammatory lung diseases such as acute respiratory distress syndrome, endothelial cell apoptosis is an inciting event in pathogenesis and a prominent pathological feature. Endothelial cell apoptosis is mediated by circulating inflammatory factors, which bind to receptors on the cell surface, activating signal transduction pathways, leading to caspase-3-mediated apoptosis. We hypothesized that yes and src have differential effects on caspase-3 activation in human pulmonary microvascular endothelial cells (hPMVEC) due to differential downstream signaling effects. To test this hypothesis, hPMVEC were treated with siRNA against src (siRNAsrc), siRNA against yes (siRNAyes), or their respective scramble controls. After recovery, the hPMVEC were treated with cytomix (LPS, IL-1β, TNF-α, and IFN-γ). Treatment with cytomix induced activation of the extracellular signal-regulated kinase (ERK) pathway and caspase-3-mediated apoptosis. Treatment with siRNAsrc blunted cytomix-induced ERK activation and enhanced cleaved caspase-3 levels, while treatment with siRNAyes enhanced cytomix-induced ERK activation and attenuated levels of cleaved caspase-3. Inhibition of the ERK pathway using U0126 enhanced cytomix-induced caspase-3 activity. Treatment of hPMVEC with cytomix induced Akt activation, which was inhibited by siRNAsrc. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway using LY294002 prevented cytomix-induced ERK activation and augmented cytomix-induced caspase-3 cleavage. Together, our data demonstrate that, in hPMVEC, yes activation blunts the ERK cascade in response to cytomix, resulting in greater apoptosis, while cytomix-induced src activation induces the phosphatidylinositol 3-kinase pathway, which leads to activation of Akt and ERK and attenuation of apoptosis., (Copyright © 2016 the American Physiological Society.)
- Published
- 2016
- Full Text
- View/download PDF
17. Resveratrol prevents hypoxia-induced arginase II expression and proliferation of human pulmonary artery smooth muscle cells via Akt-dependent signaling.
- Author
-
Chen B, Xue J, Meng X, Slutzky JL, Calvert AE, and Chicoine LG
- Subjects
- Animals, Arginase antagonists & inhibitors, Cells, Cultured, Humans, Hypertension, Pulmonary physiopathology, Hypertrophy, Right Ventricular drug therapy, Hypertrophy, Right Ventricular etiology, Hypoxia complications, Myocytes, Smooth Muscle metabolism, Rats, Resveratrol, Arginase biosynthesis, Cell Proliferation drug effects, Hypoxia physiopathology, Myocytes, Smooth Muscle drug effects, Proto-Oncogene Proteins c-akt physiology, Stilbenes pharmacology
- Abstract
Pulmonary artery smooth muscle cell (PASMC) proliferation plays a fundamental role in the vascular remodeling seen in pulmonary hypertensive diseases associated with hypoxia. Arginase II, an enzyme regulating the first step in polyamine and proline synthesis, has been shown to play a critical role in hypoxia-induced proliferation of human PASMC (hPASMC). In addition, there is evidence that patients with pulmonary hypertension have elevated levels of arginase in the vascular wall. Resveratrol, a natural polyphenol found in red wine and grape skins, has diverse biochemical and physiological actions including antiproliferative properties. Furthermore, resveratrol has been shown to attenuate right ventricular and pulmonary artery remodeling, both pathological components of pulmonary hypertension. The present studies tested the hypothesis that resveratrol would prevent hypoxia-induced pulmonary artery smooth muscle cell proliferation by inhibiting hypoxia-induced arginase II expression. Our data indicate that hypoxia-induced hPASMC proliferation is abrogated following treatment with resveratrol. In addition, the hypoxic induction of arginase II was directly attenuated by resveratrol treatment. Furthermore, we found that the inhibitory effect of resveratrol on arginase II in hPASMC was mediated through the PI3K-Akt signaling pathway. Supporting these in vitro findings, resveratrol normalized right ventricular hypertrophy in an in vivo neonatal rat model of chronic hypoxia-induced pulmonary hypertension. These novel data support the notion that resveratrol may be a potential therapeutic agent in pulmonary hypertension by preventing PASMC arginase II induction and proliferation., (Copyright © 2014 the American Physiological Society.)
- Published
- 2014
- Full Text
- View/download PDF
18. Arginase II is a target of miR-17-5p and regulates miR-17-5p expression in human pulmonary artery smooth muscle cells.
- Author
-
Jin Y, Jin Y, Chen B, Tipple TE, and Nelin LD
- Subjects
- Arginase antagonists & inhibitors, Arginase biosynthesis, Cell Hypoxia physiology, Cells, Cultured, Feedback, Humans, MicroRNAs biosynthesis, Pulmonary Artery cytology, RNA, Small Interfering metabolism, Up-Regulation, Arginase physiology, MicroRNAs physiology, Myocytes, Smooth Muscle metabolism, Pulmonary Artery metabolism
- Abstract
Vascular remodeling and smooth muscle cell proliferation are hallmark pathogenic features of pulmonary artery hypertension. MicroRNAs, endogenously expressed small noncoding RNAs, regulate gene expression at the posttranscriptional level. It has previously been shown that miR-17 overexpression in cultured human pulmonary artery smooth muscle cell (hPASMC) resulted in increased viable cell number. Previously, we have found that arginase II promotes hypoxia-induced proliferation in hPASMC. Therefore, we hypothesized that miR-17 would be upregulated by hypoxia in hPASMC and would result in greater arginase II expression. We found that levels of miR-17-5p and arginase II were significantly greater in cultured hPASMC exposed to 1% O2 for 48 h than in hPASMC exposed to 21% O2 for 48 h. Furthermore, inhibiting miR-17-5p expression decreased hypoxia-induced arginase II protein levels in hPASMC. Conversely, overexpressing miR-17-5p resulted in greater arginase II protein levels. Somewhat surprisingly, arginase II inhibition was associated with lower miR-17-5p expression in both normoxic and hypoxic hPASMC, whereas overexpressing arginase II resulted in greater miR-17-5p expression in hPASMC. These findings suggest that hypoxia-induced arginase II expression is not only regulated by miR-17-5p but also that there is a feedback loop between arginase II and miR-17-5p in hPASMC. We also found that the arginase II-mediated regulation of miR-17-5p was independent of either p53 or c-myc. We also found that l-arginine, the substrate for arginase II, and l-ornithine, the amino acid product of arginase II, were not involved in the regulation of miR-17-5p expression., (Copyright © 2014 the American Physiological Society.)
- Published
- 2014
- Full Text
- View/download PDF
19. Thioredoxin-1 mediates hypoxia-induced pulmonary artery smooth muscle cell proliferation.
- Author
-
Chen B, Nelin VE, Locy ML, Jin Y, and Tipple TE
- Subjects
- Animals, Blotting, Western, Cells, Cultured, Enzyme Inhibitors pharmacology, Humans, Hypoxia complications, Hypoxia-Inducible Factor 1, alpha Subunit genetics, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Mice, Mice, Inbred C57BL, Myocytes, Smooth Muscle metabolism, Phosphatidylinositol 3-Kinases metabolism, Phosphoinositide-3 Kinase Inhibitors, Phosphorylation drug effects, Proto-Oncogene Proteins c-akt antagonists & inhibitors, Proto-Oncogene Proteins c-akt metabolism, Pulmonary Artery metabolism, RNA, Small Interfering genetics, Signal Transduction, Thioredoxin Reductase 1 genetics, Thioredoxin Reductase 1 metabolism, Thioredoxins antagonists & inhibitors, Thioredoxins genetics, Transcription, Genetic, Cell Proliferation, Hypoxia physiopathology, Myocytes, Smooth Muscle pathology, Pulmonary Artery pathology, Thioredoxins metabolism
- Abstract
Pathological pulmonary artery smooth muscle cell (PASMC) proliferation contributes to pulmonary vascular remodeling in pulmonary hypertensive diseases associated with hypoxia. Both the hypoxia-inducible factor (HIF) and phosphatidylinositol 3-kinase (PI3K)/serine/threonine kinase (Akt) pathways have been implicated in hypoxia-induced PASMC proliferation. Thioredoxin-1 (Trx1) is a ubiquitously expressed protein that is involved in redox-dependent signaling via HIF and PI3K-Akt in cancer. The role of Trx1 in PASMC proliferation has not been elucidated. The present studies tested the hypothesis that Trx1 regulates hypoxia-induced PASMC proliferation via HIF and/or PI3K- and Akt-dependent mechanisms. Following exposure to chronic hypoxia, our data indicate that Trx1 activity is increased in adult murine lungs. Furthermore, hypoxia-induced increases in cellular proliferation are correlated with increased Trx1 expression, HIF activation, and Akt activation in cultured human PASMC. Both small-interfering RNA-mediated knockdown and pharmacological Trx1 inhibition attenuated hypoxia-induced PASMC proliferation, HIF activation, and Akt activation. While Trx1 knockdown suppressed hypoxia-induced PI3K-Akt activation in PASMC, PI3K-Akt inhibition prevented hypoxia-induced proliferation but had no effect on hypoxia-induced increases in Trx1 or HIF activation. Thus, our findings indicate that Trx1 contributes to hypoxia-induced PASMC proliferation by modulating HIF activation and subsequent PI3K-Akt activation. These novel data suggest that Trx1 might represent a novel therapeutic target to prevent hypoxic PASMC proliferation.
- Published
- 2013
- Full Text
- View/download PDF
20. Chronic hypoxia decreases arterial and venous compliance in isolated perfused rat lungs: an effect that is reversed by exogenous L-arginine.
- Author
-
Jin Y, Chen B, Calvert TJ, Chicoine LG, Liu Y, and Nelin LD
- Subjects
- Animals, Arginine metabolism, Blood Pressure drug effects, Chronic Disease, Citrulline pharmacology, Compliance, Disease Models, Animal, Dose-Response Relationship, Drug, Enzyme Inhibitors pharmacology, Hypertension, Pulmonary etiology, Hypertension, Pulmonary metabolism, Hypertension, Pulmonary physiopathology, Hypoxia complications, Hypoxia metabolism, Hypoxia physiopathology, Lung metabolism, Nitric Oxide metabolism, Nitric Oxide Donors pharmacology, Nitric Oxide Synthase antagonists & inhibitors, Nitric Oxide Synthase metabolism, Perfusion, Pulmonary Artery metabolism, Pulmonary Artery physiopathology, Pulmonary Veins metabolism, Pulmonary Veins physiopathology, Rats, Rats, Sprague-Dawley, Time Factors, Vascular Resistance drug effects, Vasoconstriction drug effects, Ventricular Dysfunction, Right etiology, Ventricular Dysfunction, Right metabolism, Ventricular Dysfunction, Right physiopathology, Arginine pharmacology, Hemodynamics drug effects, Hypertension, Pulmonary drug therapy, Hypoxia drug therapy, Lung blood supply, Pulmonary Artery drug effects, Pulmonary Veins drug effects, Ventricular Dysfunction, Right drug therapy
- Abstract
Chronic hypoxia (CH)-induced pulmonary hypertension is characterized by vasoconstriction and vascular remodeling, leading to right ventricular dysfunction. Given the role of arterial compliance (C(a)) in right ventricular work, a decrease in C(a) would add to right ventricular work. Nitric oxide (NO) is a potent vasodilator made by NO synthases from L-arginine (L-Arg). However, little is known of the effect of L-Arg on vascular compliance (C(v)) in the lung. We hypothesized that exposure to CH would decrease C(a) and that this effect would be reversed by exogenous L-Arg. Sprague-Dawley rats were exposed to either normoxia or CH for 14 days; the lungs were then isolated and perfused. Vascular occlusions were performed and modeled using a three-compliance, two-resistor model. Pressure-flow curves were generated, and a distensible vessel model was used to estimate distensibility and a vascular resistance parameter (R(0)). Hypoxia resulted in the expected increase in arterial resistance (R(a)) as well as a decrease in both C(a) and C(v). L-Arg had little effect on R(a), C(a), or C(v) in isolated lungs from normoxic animals. L-Arg decreased R(a) in lungs from CH rats and redistributed compliance to approximately that found in normoxic lungs. CH increased R(0), and L-Arg reversed this increase in R(0). L-Arg increased exhaled NO, and inhibition of L-Arg uptake attenuated the L-Arg-induced increase in exhaled NO. These data demonstrate that the CH-induced decrease in C(a) was reversed by L-Arg, suggesting that L-Arg may improve CH-induced right ventricular dysfunction.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.